Literature DB >> 20967403

[Do opioids induce hyperalgesia?].

C Zöllner1.   

Abstract

Opioids are the most potent drugs for treatment of acute and chronic pain. However, accumulating evidence suggests that opioids may paradoxically also enhance pain, often referred to as opioid-induced hyperalgesia. Opioid-induced hyperalgesia is defined as an increased sensitivity to pain or a decreased pain threshold in response to opioid therapy. Several mechanisms have been proposed to support opioid-induced hyperalgesia. However, it remains unclear whether opioid-induced hyperalgesia develops during continuous chronic application of opioids or on their withdrawal. This review provides a comprehensive summary of clinical research concerning opioid-induced hyperalgesia and the molecular mechanisms of opioid withdrawal and opioid tolerance and other potential mechanisms which might induce hyperalgesia during opioid therapy will be discussed. The status quo of our knowledge will be summarized and the clinical relevance of opioid-induced hyperalgesia will be discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20967403     DOI: 10.1007/s00101-010-1803-x

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  86 in total

Review 1.  Paradoxical signal transduction in neurobiological systems.

Authors:  F C Colpaert; Y Frégnac
Journal:  Mol Neurobiol       Date:  2001 Aug-Dec       Impact factor: 5.590

Review 2.  Postoperative hyperalgesia: its clinical importance and relevance.

Authors:  Oliver H G Wilder-Smith; Lars Arendt-Nielsen
Journal:  Anesthesiology       Date:  2006-03       Impact factor: 7.892

3.  No tolerance to peripheral morphine analgesia in presence of opioid expression in inflamed synovia.

Authors:  C Stein; M Pflüger; A Yassouridis; J Hoelzl; K Lehrberger; C Welte; A H Hassan
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

4.  Changing M3G/M6G ratios and pharmacodynamics in a cancer patient during long-term morphine treatment.

Authors:  Gertrud Andersen; Lona L Christrup; Per Sjøgren; Steen Honoré Hansen; Niels-Henrik Jensen
Journal:  J Pain Symptom Manage       Date:  2002-02       Impact factor: 3.612

5.  Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli.

Authors:  Luda Diatchenko; Andrea G Nackley; Gary D Slade; Kanokporn Bhalang; Inna Belfer; Mitchell B Max; David Goldman; William Maixner
Journal:  Pain       Date:  2006-07-11       Impact factor: 6.961

6.  Morphine-6-glucuronide: analgesic effects and receptor binding profile in rats.

Authors:  F V Abbott; R M Palmour
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

7.  Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine.

Authors:  Per Sjøgren; Torsten Jonsson; Niels-Henrik Jensen; Niels-Erik Drenck; Troels Staehelin Jensen
Journal:  Pain       Date:  1993-10       Impact factor: 6.961

Review 8.  Antinociceptive and nociceptive actions of opioids.

Authors:  Michael H Ossipov; Josephine Lai; Tamara King; Todd W Vanderah; T Philip Malan; Victor J Hruby; Frank Porreca
Journal:  J Neurobiol       Date:  2004-10

Review 9.  Relationships among morphine metabolism, pain and side effects during long-term treatment: an update.

Authors:  Gertrud Andersen; Lona Christrup; Per Sjøgren
Journal:  J Pain Symptom Manage       Date:  2003-01       Impact factor: 3.612

10.  Opioid and adenosine peripheral antinociception are subject to tolerance and withdrawal.

Authors:  K O Aley; P G Green; J D Levine
Journal:  J Neurosci       Date:  1995-12       Impact factor: 6.167

View more
  2 in total

1.  [Opioids : a dark side as well as a light side?].

Authors:  W Koppert
Journal:  Anaesthesist       Date:  2010-11       Impact factor: 1.041

2.  Enhanced inhibitory synaptic transmission in the spinal dorsal horn mediates antinociceptive effects of TC-2559.

Authors:  Long-Zhen Cheng; Lei Han; Jing Fan; Lan-Ting Huang; Li-Chao Peng; Yun Wang
Journal:  Mol Pain       Date:  2011-08-04       Impact factor: 3.395

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.